New data shows abemaciclib continues to benefit high-risk, HR+, HER2-, early-stage br

[News]

Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

More... (https://www.news-medical.net/news/20201209/New-data-shows-abemaciclib-continues-to-benefit-high-risk-HR2b-HER2-early-stage-breast-cancer-patients.aspx)